vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -12.9%, a 109.2% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -0.4%). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
ACAD vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $340.0M |
| Net Profit | $273.6M | $-13.9M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | -17.2% |
| Net Margin | 96.3% | -12.9% |
| Revenue YoY | 9.4% | -0.4% |
| Net Profit YoY | 90.3% | -131.0% |
| EPS (diluted) | $1.61 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $340.0M | ||
| Q3 25 | $278.6M | $337.7M | ||
| Q2 25 | $264.6M | $319.2M | ||
| Q1 25 | $244.3M | $237.4M | ||
| Q4 24 | $259.6M | $341.5M | ||
| Q3 24 | $250.4M | $292.3M | ||
| Q2 24 | $242.0M | $270.7M | ||
| Q1 24 | $205.8M | $228.1M |
| Q4 25 | $273.6M | $-13.9M | ||
| Q3 25 | $71.8M | $33.5M | ||
| Q2 25 | $26.7M | $34.0M | ||
| Q1 25 | $19.0M | $2.8M | ||
| Q4 24 | $143.7M | $44.8M | ||
| Q3 24 | $32.8M | $28.8M | ||
| Q2 24 | $33.4M | $22.7M | ||
| Q1 24 | $16.6M | $11.9M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | -17.2% | ||
| Q3 25 | 12.8% | 13.6% | ||
| Q2 25 | 12.2% | 14.5% | ||
| Q1 25 | 7.9% | 2.2% | ||
| Q4 24 | 59.1% | 15.3% | ||
| Q3 24 | 12.6% | 12.8% | ||
| Q2 24 | 12.6% | 10.4% | ||
| Q1 24 | 7.4% | 6.0% |
| Q4 25 | 96.3% | -12.9% | ||
| Q3 25 | 25.8% | 9.9% | ||
| Q2 25 | 10.1% | 10.6% | ||
| Q1 25 | 7.8% | 1.2% | ||
| Q4 24 | 55.4% | 13.1% | ||
| Q3 24 | 13.1% | 9.9% | ||
| Q2 24 | 13.8% | 8.4% | ||
| Q1 24 | 8.0% | 5.2% |
| Q4 25 | $1.61 | $-0.41 | ||
| Q3 25 | $0.42 | $0.98 | ||
| Q2 25 | $0.16 | $0.99 | ||
| Q1 25 | $0.11 | $0.08 | ||
| Q4 24 | $0.86 | $1.32 | ||
| Q3 24 | $0.20 | $0.85 | ||
| Q2 24 | $0.20 | $0.67 | ||
| Q1 24 | $0.10 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $299.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.7B |
| Total Assets | $1.6B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $299.3M | ||
| Q3 25 | $258.0M | $274.8M | ||
| Q2 25 | $253.6M | $233.7M | ||
| Q1 25 | $217.7M | $181.0M | ||
| Q4 24 | $319.6M | $279.3M | ||
| Q3 24 | $155.1M | $179.8M | ||
| Q2 24 | $177.1M | $208.1M | ||
| Q1 24 | $204.7M | $216.5M |
| Q4 25 | $1.2B | $1.7B | ||
| Q3 25 | $917.3M | $1.8B | ||
| Q2 25 | $822.4M | $1.8B | ||
| Q1 25 | $765.2M | $1.7B | ||
| Q4 24 | $732.8M | $1.7B | ||
| Q3 24 | $577.2M | $1.7B | ||
| Q2 24 | $516.7M | $1.7B | ||
| Q1 24 | $464.0M | $1.7B |
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.3B | $5.8B | ||
| Q2 25 | $1.2B | $4.7B | ||
| Q1 25 | $1.1B | $4.5B | ||
| Q4 24 | $1.2B | $4.4B | ||
| Q3 24 | $976.9M | $4.6B | ||
| Q2 24 | $914.1M | $4.2B | ||
| Q1 24 | $855.1M | $3.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-664.3M |
| Free Cash FlowOCF − Capex | — | $-680.1M |
| FCF MarginFCF / Revenue | — | -200.0% |
| Capex IntensityCapex / Revenue | — | 4.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-664.3M | ||
| Q3 25 | $74.3M | $-948.1M | ||
| Q2 25 | $64.0M | $-238.5M | ||
| Q1 25 | $20.3M | $-281.1M | ||
| Q4 24 | $40.4M | $129.4M | ||
| Q3 24 | $63.2M | $-202.0M | ||
| Q2 24 | $25.0M | $-237.8M | ||
| Q1 24 | $29.1M | $38.4M |
| Q4 25 | — | $-680.1M | ||
| Q3 25 | $73.9M | $-950.4M | ||
| Q2 25 | — | $-241.0M | ||
| Q1 25 | — | $-284.7M | ||
| Q4 24 | — | $116.4M | ||
| Q3 24 | $63.2M | $-204.0M | ||
| Q2 24 | — | $-241.7M | ||
| Q1 24 | — | $35.2M |
| Q4 25 | — | -200.0% | ||
| Q3 25 | 26.5% | -281.5% | ||
| Q2 25 | — | -75.5% | ||
| Q1 25 | — | -120.0% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 25.2% | -69.8% | ||
| Q2 24 | — | -89.3% | ||
| Q1 24 | — | 15.4% |
| Q4 25 | — | 4.6% | ||
| Q3 25 | 0.1% | 0.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | -28.34× | ||
| Q2 25 | 2.40× | -7.02× | ||
| Q1 25 | 1.07× | -102.07× | ||
| Q4 24 | 0.28× | 2.89× | ||
| Q3 24 | 1.93× | -7.01× | ||
| Q2 24 | 0.75× | -10.49× | ||
| Q1 24 | 1.76× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
WD
Segment breakdown not available.
